Stockwinners Market Radar for June 14, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:05 EDT Cathie Wood's ARK Investment bought 32K shares of Trade Desk today

18:58 EDT New Relic COO Kristy Friedrich resigns - In a regulatory filing, New Relic disclosed that its COO Kristy Friedrichs resigned from her role as the Company's Chief Operating Officer effective December 31, 2023, which follows a period of transition. Also on June 11, 2023, Lew Cirne, the company's Founder and Executive Chair, agreed with the ompany that he will transition from his role as Executive Chair to the role of Non-Executive Chair of the Board, effective upon the conclusion of the company's Annual Meeting of Stockholders on August 16, 2023, and thereby end his employment relationship with the company.

18:47 EDT Estee Lauder to present preclinical results on anti-aging products at WCD - Earlier today, Estee Lauder "announced that the company and its brands will present at the 25th World Congress of Dermatology (WCD) in Singapore from July 3-8, 2023. ELC researchers across 3 brands and ELC Research & Development will share novel clinical and preclinical results that demonstrate scientific innovation and leadership across emerging areas of skin health and anti-aging in the form of 5 poster presentations and a satellite symposium during this global event, which takes place every 4 years." "We are thrilled to share key findings at the upcoming WCD from our most recent research efforts, which leverage insights from the fields of longevity and epigenetics to advance our understanding of the molecular pathways underlying inflammation and aging," said Nadine Pernodet, PhD, Senior Vice President, Bioscience, ELC. "The breadth and depth of data to be presented further reflects our robust combined R&D and clinical testing capabilities. These highly integrated areas of focus support our exploration of new ingredients or methodologies to ultimately help shape and advance the skin care landscape." Shares of Estee Lauder were up 4.1% in today's trading, closing at $192.16.

18:24 EDT Ameren exec sells $3.04M in common stock - In a regulatory filing, Ameren disclosed that its Chief Nuclear Officer Fadi Diya sold 37K shares of common stock on June13th in a total transaction size of $3.04M.

18:11 EDT Robinhood CCO Bhatt sells 92,987 class A shares - In a regulatory filing, Robinhood chief creative officer Baiju Bhatt disclosed the sale of 92,987 class A common shares of the company on June 12 at a price of $9.3328 per share.

17:59 EDT Four Corners Property Trust acquires Fast Pace Healthy property for $2.1M - Four Corners Property Trust announced the acquisition of a Fast Pace Health property for $2.1M. The property is newly constructed and located in a strong retail corridor in Louisiana and is occupied under a long-term net lease. The transaction was priced at a cap rate in range with previous FCPT transactions.

17:54 EDT US senators propose bill to eliminate Section 230 protection for AI companies - "U.S. Senators Josh Hawley R-Mo. and Richard Blumenthal D-Conn, the Ranking Member and the Chair of the Senate Judiciary Subcommittee on Privacy, Technology, and the Law, respectively - introduced the No Section 230 Immunity for AI Act. This new bipartisan legislation would clarify that Section 230 immunity will not apply to claims based on generative AI, ensuring consumers have the tools they need to protect themselves from harmful content produced by the latest advancements in AI technology.For example, AI-generated "deepfakes" - lifelike false images of real individuals - are exploding in popularity. Ordinary people can now suffer life-destroying consequences for saying things they never said, or doing things they never would. Companies complicit in this process should be held accountable in court."We can't make the same mistakes with generative AI as we did with Big Tech on Section 230," said Senator Hawley. "When these new technologies harm innocent people, the companies must be held accountable. Victims deserve their day in court and this bipartisan proposal will make that a reality." "AI companies should be forced to take responsibility for business decisions as they're developing products-without any Section 230 legal shield," said Senator Blumenthal. "This legislation is the first step in our effort to write the rules of AI and establish safeguards as we enter this new era. AI platform accountability is a key principle of a framework for regulation that targets risk and protects the public." The Fly notes that companies like Alphabet (GOOG), Microsoft (MSFT), Amazon (AMZN), Apple (AAPL), Nvidia (NVDA), IBM (IBM), Meta Platforms (META) and Intel (INTC). Reference Link

17:41 EDT Google debuts 'Virtual try-on' as AI feature for shoppers - Senior Director of Product at Google, Lilian Rincon blogged in part on the company's Keyword blog: "Apparel is one of the most-searched shopping categories, most online shoppers agree: It's hard to know what clothes will look like on you before you buy them...Now, thanks to our new virtual try-on tool on Search, you can see whether a piece is right for you before you buy it. Virtual try-on for apparel shows you how clothes look on a variety of real models. Here's how it works: Our new generative AI model can take just one clothing image and accurately reflect how it would drape, fold, cling, stretch and form wrinkles and shadows on a diverse set of real models in various poses...Starting today, U.S. shoppers can virtually try on women's tops from brands across Google, including Anthropologie, Everlane, H&M and LOFT. Just tap products with the "Try On" badge on Search and select the model that resonates most with you...Our new guided refinements can help U.S. shoppers fine-tune products until you find the perfect piece. Thanks to machine learning and new visual matching algorithms, you can refine using inputs like color, style and pattern. And unlike shopping in a store, you're not limited to one retailer: You'll see options from stores across the web. You can find this feature, available for tops to start, right within product listings...We believe that AI will continue to improve our lives in ways big and small, including making everyday activities like shopping just a bit more helpful and fun . Stay tuned for more ways we're using advanced technology like AI to help you shop online with confidence." Reference Link

17:19 EDT CACI awarded $125.54M Navy contract - CACI was awarded a $125.54M cost-plus-fixed-fee, cost reimbursable indefinite-delivery/indefinite-quantity contract. This contract provides production, fabrication, integration, logistics, sustainment, design, analysis, testing, verification, technical, and project management support. These services are in support of developing and providing a full range of crisis response and interoperable command, control, communications, computers, combat electronic systems solutions and products to facilitate communications and knowledge transfer at crisis locations worldwide. This includes supporting the operational requirements of the current CRIC-ES developed systems, modifications and enhancements for these systems, and developing and maintaining solutions and products for multiple Naval Air Systems Command, or NAVAIR, and non-NAVAIR customers. Work is expected to be completed in August 2028. No funds will be obligated at the time of award; funds will be obligated on individual orders as they are issued. This contract was competitively procured via an electronic request for proposal; two offers were received. The Naval Air Warfare Center Aircraft Division is the contracting activity.

17:09 EDT Gold Resource: 2023 drilling campaign is returning positive results - Gold Resource is pleased to provide an update on results for the ongoing expansion and infill drill programs at the Don David Gold Mine, DDGM, which continue to provide evidence of adding additional higher grade resources from the north-west Arista, south-central Switchback, the Three Sisters and newly discovered Gloria vein systems. "The 2023 drilling campaign is returning positive results and has further confirmed that the program is on the right track to deliver higher grade resources into the near- and mid-term mine plan," stated Allen Palmiere, President and CEO for the Company.

16:57 EDT Nvidia director sells $48.3M in common stock - In a regulatory filing, Nvidia disclosed that its director Harvey Jones sold 119.8K shares of common stock on June 13th in a total transaction size of $48.3M.

16:50 EDT OncoSec trading halted, news pending

16:41 EDT Lennar sees Q3 new orders 18,000-19,000 - Sees Q3 average sales price "consistent with Q2."

16:39 EDT Lennar reports Q2 deliveries of 17,074 homes - Reports Q2: New orders of 17,885 homes with a dollar value of $8.2B; Backlog of 20,214 homes with a dollar value of $9.5B.

16:36 EDT Chimera increases buyback program to $250M - Chimera Board of Directors of the Company has authorized an increase in the amount authorized under the Company's common stock repurchase program. As of March 31, 2023, $177 million in aggregate amount of common stock remained available for repurchase under the program. Following the Board's action, the aggregate amount of common stock available for repurchase under the program is $250 million.

16:35 EDT Philips to repurchase 7.1M shares for $132M to cover incentive plans - Philips announced that it will repurchase up to 7.1M shares to cover certain of its obligations arising from its long-term incentive plans. At the current share price, the shares represent an amount of up to approximately EUR 132M. The repurchases will be executed through one or more individual forward transactions, expected to be entered into in the second and/or the third quarter of 2023, in accordance with the Market Abuse Regulation and within the limits of the authorization granted by the company's General Meeting of Shareholders on May 9.

16:33 EDT AutoZone authorizes additional $2B under share repurchase program - AutoZone announced its board of directors authorized the repurchase of an additional $2B of the company's common stock in connection with its ongoing share repurchase program.

16:32 EDT Host Hotels boosts dividend 25% to 15c per share - Host Hotels & Resorts announced that its board of directors authorized a regular quarterly cash dividend of 15c per share, a 25% increase over the prior quarter. The dividend is payable on July 17 to stockholders of record on June 30.

16:31 EDT Premier to divest non-healthcare GPO operations for $800M - Premier "announced that it has entered into a definitive agreement with OMNIA Partners, a leading non-healthcare group purchasing organization, under which Premier will divest its non-healthcare GPO operations for approximately $800 million in cash, subject to certain purchase price adjustments. Following the close of the transaction, OMNIA will become the primary GPO for Premier's non-healthcare members, which include educational, hospitality and recreation organizations, and will provide support to the channel partners that service non-healthcare GPO members. These members will continue to have access to the Premier GPO portfolio. The transaction will have no impact on Premier's healthcare businesses, and the Company will maintain all existing healthcare contracts, services, solutions and programs."

16:22 EDT Johnson & Johnson exec Wengel sells 12,465 common shares - In a regulatory filing, Johnson & Johnson chief TO and risk officer Kathryn Wengel disclosed the sale of 12,465 common shares of the company on June 12 at a price of $160 per share.

16:17 EDT Environmental Tectonics announcesTimothy Kennedy as CFO - Environmental Tectonics announces the appointment of Timothy Kennedy, CPA, CMA as the Company's Chief Financial Officer and Treasurer.

16:16 EDT Bowman Consulting completes 100 BESS engineering assignments - Bowman Consulting Group nationwide. The recent passing of the "Fiscal Responsibility Act of 2023" included provisions that enable fast tracking of permitting for the battery storage industry under the 2015 FAST Act (Section 41001(6)(A)). Bowman's implementation milestone serves as a proven track record for providing developers with the full-service support required to realize the rapid market expansion enabled by the new legislation. Bowman provides complete implementation support from site identification and acquisition, through land survey, preliminary engineering, environmental due diligence, and interconnect application, to full electrical & civil design, and construction management.

16:16 EDT Opera announces first semi-annual dividend of 40c per share - Opera announced that its Board of Directors has adopted a recurring semi-annual cash dividend program for holders of Opera's ordinary shares as well as American Depositary Shares, each representing two ordinary shares. Opera's first semi-annual dividend under the program will be 40c per ADS. Payment will be made to shareholders of record as of the close of business on June 30. Dividends to be paid to the holders of ADSs through the depositary bank, The Bank of New York Mellon, will be subject to the terms of the deposit agreement. The company expects the depositary bank to distribute dividends on or about July 12.

16:14 EDT Airspan Networks discloses NYSE non-compliance notice - Airspan Networks announced that it has received a letter from the NYSE American LLC stating that it is not in compliance with the continued listing standards set forth in Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. Section 1003(a)(i) requires a listed company to have stockholders' equity of $2 million or more if the listed company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years. Section 1003(a)(ii) requires a listed company to have stockholders' equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Company reported a stockholders' deficit of $99.9 million as of March 31, 2023, and has had losses from continuing operations and/or net losses in each of its three most recent fiscal years.

16:08 EDT TrueCar CEO Michael Darrow to depart, Jantoon Reigersman to succeed - TrueCar announced the appointment of Jantoon Reigersman as President and CEO. Reigersman succeeds Michael Darrow, who is departing TrueCar and vacating his position on the Board. Jantoon Reigersman recently served as TrueCar's Chief Operating Officer since March 2022. From January 2021 to February 2023, he also served as our Chief Financial Officer. Before joining TrueCar, he served from December 2017 to May 2020 as the Chief Financial Officer of Leaf Group, Ltd., a diversified Internet, media and e-commerce company, and from January 2014 until joining Leaf, he served as Chief Financial officer of Ogin, Inc., a clean technology company. Before then, he was in the Special Situations Group at Goldman Sachs and in M&A investment banking at Morgan Stanley.

16:04 EDT Allegiant Travel reports May total system passengers down 3.3% y/y - Reports May total system: Available seat miles down 1.6% y/y; Departures down 2.3% y/y. Reports May scheduled service passengers down 3.4% y/y; Revenue passenger miles down 3% y/y; Available seat miles down 2.2%; Load factor down 0.7 pts; Departures down 3%.

15:16 EDT Citi on track to buyback $1B in stock this quarter - Says resumed buybacks this quarter. Comments taken from Morgan Stanley U.S. Financials, Payments, and CRE Conference.

15:09 EDT Bill Gates to meet Chinese President Xi Jinping this week, Reuters says - Microsoft co-founder Bill Gates is scheduled to have a meeting with the President of China Xi Jinping this Friday, wrote Julie Zhu for Reuters, citing sources. "The meeting will mark Xi's first meeting with a foreign private entrepreneur in recent years," noted Reuters in the story. Reference Link

13:53 EDT North American rail traffic down 5.1% for the week ending June 10 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending June 10. For this week, total U.S. weekly rail traffic was 471,141 carloads and intermodal units, down 5.9% compared with the same week last year. Total carloads for the week ending June 10 were 228,988 carloads, up 0.6% compared with the same week in 2022, while U.S. weekly intermodal volume was 242,153 containers and trailers, down 11.2% compared to 2022. North American rail volume for the week ending June 10 on 12 reporting U.S., Canadian and Mexican railroads totaled 333,155 carloads, up 0.5% compared with the same week last year, and 326,138 intermodal units, down 10.2% compared with last year. Total combined weekly rail traffic in North America was 659,293 carloads and intermodal units, down 5.1%. North American rail volume for the first 23 weeks of 2023 was 14,835,217 carloads and intermodal units, down 4.2% compared with 2022. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific Kansas City (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX), FreightCar America (RAIL) and Wabtec (WAB). Reference Link

13:03 EDT Gambling.com notes bill to allow legal online sports betting in North Carolina - Gambling.com noted the signing of House Bill 347 to allow legal, regulated online sports betting across North Carolina - becoming the 28th state to do so. HB 347 requires the state lottery to publish online sports betting regulations by January 8, 2024, and to authorize sports betting operators to start accepting wagers within one year from today, the company stated. Charles Gillespie, Gambling.com Group CEO, said, "Kevin [McCrystle] and I started our journey to build the pre-eminent online gambling affiliate operator in 2006 from an idea that formed in a dorm room in Chapel Hill, and which quickly led us abroad to find regulated markets where we could apply our expertise and passion. Our journey to building one of the world's leading online gambling performance marketing companies has now come full circle with the legalization of online sports betting in North Carolina. I applaud and congratulate the State's General Assembly leaders and Governor Cooper for making regulated online sports betting a reality. The next generation of North Carolina entrepreneurs will be able to dive straight into opportunities in this exciting industry."

12:16 EDT Sony testing cloud streaming for supported PlayStation 5 games - In a blog post, Sony said that it is currently testing cloud streaming for supported PlayStation 5 games - this includes PS5 titles from the PlayStation Plus Game Catalog and Game Trials, as well as supported digital PS5 titles that players own. "When this feature launches, cloud game streaming for supported PS5 titles will be available for use directly on your PS5 console," said Nick Maguire, VP of Global Services, Global Sales, and Business Operations at Sony Interactive Entertainment. "That means as a Premium member, it'll be easier to jump into your favorite games without downloading them first onto your PS5 console. Our goal is to add this as an additional benefit to PlayStation Plus Premium as part of our ongoing efforts to enhance the value of PlayStation Plus. We think it's important for Premium members to be able to enjoy as many games as possible via cloud streaming. As more games continue to launch on the PS5 console, we look forward to adding cloud streaming capability for PS5 titles in addition to the PS3, PS4 and classic titles that are already available for Premium members to stream. We're in the early stages right now, and we can't wait to share more details when we're ready, including a launch time frame. Stay tuned!" Reference Link

12:00 EDT Agilon Health falls -12.7% - Agilon Health is down -12.7%, or -$2.67 to $18.39.

12:00 EDT Gol Linhas rises 12.4% - Gol Linhas is up 12.4%, or 50c to $4.54.

12:00 EDT Coherent rises 19.2% - Coherent is up 19.2%, or $8.21 to $51.03.

11:31 EDT Aclarion enters commercial agreement with The Imaging Center - Aclarion announced their commercial agreement with The Imaging Center in Grand Rapids, MI. The Imaging Center is a new medical imaging center in the greater Grand Rapids market serving physicians who demand core imaging capabilities, as well as solutions like Nociscan.

11:11 EDT IBM announces 'breakthrough' published on quantum computers - IBM announced a new "breakthrough," published on the cover of the scientific journal Nature, demonstrating that quantum computers can produce accurate results at a scale of 100+ qubits reaching beyond leading classical approaches. In their experiment, the IBM team demonstrates that it is possible for a quantum computer to outperform leading classical simulations by learning and mitigating errors in the system. The team used the IBM Quantum 'Eagle' quantum processor composed of 127 superconducting qubits on a chip to generate large, entangled states that simulate the dynamics of spins in a model of material and accurately predict properties such as its magnetization. "This is the first time we have seen quantum computers accurately model a physical system in nature beyond leading classical approaches," said Dario Gil, Senior Vice President and Director of IBM Research. "To us, this milestone is a significant step in proving that today's quantum computers are capable, scientific tools that can be used to model problems that are extremely difficult - and perhaps impossible - for classical systems, signaling that we are now entering a new era of utility for quantum computing."

11:02 EDT Five Below names Kristy Chipman CFO and treasurer, succeeding Ken Bull - Five Below announced that Kristy Chipman will join the company as CFO and Treasurer on July 17, 2023, reporting to Joel Anderson, President and CEO. Chipman will lead the company's finance and accounting organization, overseeing SEC reporting and financial operations, financial planning & analysis, investor relations, internal audit, enterprise risk management, tax and treasury, and serve as the company's principal financial officer and principal accounting officer. Chipman succeeds Ken Bull, who, as previously announced, has assumed the new role of COO of Five Below. Chipman most recently served as Executive Vice President, CFO and COO at Ruth's Chris Hospitality Group.

11:00 EDT Sonos announces 7% reduction in workforce - In a regulatory filing, Sonos said, "On June 14, 2023, Sonos announced a reduction in force involving approximately 7% of our employees. Decisions regarding the elimination of positions are subject to local law and consultation requirements in certain countries. The Company also committed to further reducing its real estate footprint and re-evaluating certain program spend. The foregoing actions were committed to on June 13, 2023 and reflect the Company's commitment to rightsize its cost base while still investing in its product roadmap to drive future growth. The Company estimates that it will incur approximately $11 to $14M of restructuring and related charges, of which $9 to $11M is related to employee severance and benefits costs. The Company expects to incur substantially all of the restructuring and related charges in the third quarter of fiscal 2023."

10:26 EDT BRT Apartments increases share repurchase authorization to $10M - BRT Apartments announced the Board of Directors has extended the term of the company's share repurchase program from December 31, 2023 to December 31, 2025 and increased the share repurchase authorization to up to $10M, inclusive of the approximate $1.99M remaining under the 2023 Program. Since announcing on May 15, 2023 that BRT may redeploy a portion of the $19.4M in net proceeds from its recent disposition of Chatham Court and Reflections, among other things, to fund potential stock repurchases, the company has repurchased 166,565 shares at a weighted average price of approximately $18.09 per share.

10:01 EDT Cineverse acquires North American distribution rights to 'On Fire' - Cineverse announced that the Company has acquired all North American rights to the pulse-pounding survival and inspirational drama On Fire. Inspired by the true and harrowing events which transpired during one of Northern California's most catastrophic wildfires, the film premiered at the 2023 Mammoth Film Festival where it was nominated for best genre film.

10:00 EDT Humana falls -13.5% - Humana is down -13.5%, or -$69.14 to $443.49.

10:00 EDT Universal Health rises 7.7% - Universal Health is up 7.7%, or $10.92 to $151.89.

10:00 EDT Coherent rises 20.5% - Coherent is up 20.5%, or $8.76 to $51.58.

09:58 EDT T-Mobile, Google Cloud partnering on 5G Advanced Network Solutions - T-Mobile (TMUS) and Google Cloud (GOOGL) announced they are working together to "combine the power of 5G and edge compute, giving enterprises more ways to embrace digital transformation." T-Mobile will connect the 5G ANS suite of public, private and hybrid 5G networks with Google Distributed Cloud Edge, or "GDC Edge," to help customers embrace next-generation 5G applications and use cases, like AR/VR experiences, the companies stated. "This partnership brings together the powerful combination of 5G and edge computing to unlock the expansion of technologies such as AR and VR from limited applications to large-scale adoption. From providing a shopping experience in a virtual reality environment to improving safety through connected sensors or computer vision technologies, T-Mobile's 5G ANS combined with Google Cloud's innovative edge compute technology can bring the connected world to businesses across the country," said Mishka Dehghan, Senior Vice President, Strategy, Product, and Solutions Engineering, T-Mobile Business Group.

09:47 EDT Humana falls -11.1% - Humana is down -11.1%, or -$57.03 to $455.60.

09:47 EDT II-VI rises 12.9% - II-VI is up 12.9%, or $25.38 to $222.64.

09:47 EDT Community Health rises 15.4% - Community Health is up 15.4%, or 63c to $4.73.

09:37 EDT Terran Orbital announces Tony Gingiss as COO - Terran Orbital Corporation announced aerospace and defense industry veteran Tony Gingiss has joined Terran Orbital as the company's new COO. We are thrilled Tony has chosen to become a Terran," said Terran Orbital Co-Founder, Chairman, and CEO Marc Bell. "Tony will bring an innovative and experienced edge to Terran Orbital as we expand our facilities and build out our contracts. We look forward to working with Tony and growing with his guidance."

09:30 EDT WeTrade Group Inc trading halted, volatility trading pause

09:26 EDT Vuzix announces distribution agreement with ASK - Vuzix announced that it has entered into a distribution agreement with ASK Corporation, a Tokyo-based leading distributor providing products, services and solutions to consumer, commercial, and professional users of IT equipment. Vuzix has received and is now shipping against a large volume purchase order from ASK, who will distribute Vuzix products to its customers across Japan. The agreement marks a significant milestone in the advancement of AR technology and its widespread adoption in Japan.

09:21 EDT Camber Energy, Viking Energy announce effectiveness of regstration statement - Camber Energy announced that on June 13, 2023, at 4:00 p.m. ET, the U.S. Securities and Exchange Commission declared effective the Registration Statement on Form S-4, as amended filed with the SEC in connection with the previously announced proposed business combination of Camber and Viking. The Registration Statement provides important information about the Merger. The companies also established a record date of May 22, 2023 and announced that: Camber will hold its special meeting of stockholders on July 20, 2023 at 10:00 a.m. to approve the Merger and related matters; and Viking will hold its special meeting of stockholders on July 20, 2023 at 2:00 p.m. to approve the Merger and related matters. The stockholders of record of Camber as of the Record Date will be entitled to notice of, and to vote at or before, the Camber Special Meeting. The stockholders of record of Viking as of the Record Date will be entitled to notice of, and to vote at or before, the Viking Special Meeting. If the necessary proposals at the Special Meeting are approved, Camber and Viking anticipate that the Merger will close effective on or about August 1, 2023, subject to the satisfaction of all other closing conditions. Upon the closing of the Merger, a wholly-owned subsidiary of Camber will merger with and into Viking, with Viking surviving the Merger as a wholly-owned subsidiary of Camber and Camber remaining the sole publicly-traded entity.

09:18 EDT Stitch Fix appoints Matt Baer as CEO - Stitch Fix (SFIX) announced that Matt Baer, former Chief Customer & Digital Officer at Macy's (M), has been appointed CEO and a member of the Board of Directors, effective June 26, 2023. Founder, interim CEO and Executive Chairperson of the Board Katrina Lake will work closely with Baer as he transitions into his role. Lake will continue on in her role as Executive Chairperson of the Board.

09:14 EDT TAT Technologies receives first order for repair of APU331-500 - TAT Technologies informed on receiving a first customer's order for the repair of APU331-500 from one of North America Cargo carriers. Zamir CEO and President of TAT Technologies said:" this order is the first of many orders to come, part of our penetration strategy to the MRO market of the APU 331-500. Establishing this line of business after 2 years of investment is a breakthrough that will serve our growth strategy for the coming years, as well as improve our margins and profits." Zamir added:" Last week we announced our results for the first quarter of 2023 which was the second consecutive quarter of increase in revenues, gross profits and margins, EBITDA, and the shift to net profits. We expect the improvement in our results to continue in the coming quarters, and such improvement to enhance the value to our shareholders".

09:12 EDT Eldorado Gold announces closing of C$81.5M strategic investment by the EBRD - Eldorado Gold Corporation announced the closing of the previously announced strategic investment of C$81.5M by the European Bank for Reconstruction and Development, EBRD. The investment was effected by way of a private placement whereby EBRD subscribed for 6,269,231 shares at a price of C$13.00 per share. The Private Placement is subject to final acceptance of the Toronto Stock Exchange.

09:12 EDT Lumu integrates with SentinelOne for network detection, response - Lumu announced its integration with SentinelOne that will provide organizations with the ability to continuously monitor their network for adversarial activity and gain broader visibility into assets impacted by cyberattacks. Lumu and SentinelOne's solutions will work together to provide powerful protection against malicious activity discovered in the network.

09:08 EDT Lava Therapeutics announces it will discontinue LAVA-051's clinical trial - LAVA Therapeutics announced its decision to rationalize its pipeline and prioritize its lead solid tumor program. The Company will continue to advance LAVA-1207, its Gammabody program designed to target the prostate-specific membrane antigen as well as earlier stage programs. The ongoing clinical trial of LAVA-051 targeting CD1d expressing hematological tumors, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia will be discontinued. LAVA-051 was being evaluated in an open-label, multi-center Phase 1/2a clinical trial in patients with relapsed or refractory CLL and MM to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary anti-tumor activity of LAVA-051. The decision to discontinue LAVA-051's clinical trial follows a recent review of the competitive landscape that has continued to evolve. The decision is not due to safety concerns. "We started this trial to investigate the potential for a bispecific gamma-delta T cell engager to help patients with hematological malignancies. We are pleased the trial data to date showed a favorable safety profile, gamma delta T cell activation, and early signals of potential anti-tumor activity in CLL and MM," said Steve Hurly, chief executive officer at LAVA. "However, there have been significant advancements in the treatment of multiple myeloma and chronic lymphocytic leukemia. As a result, we have decided to discontinue this trial and focus our resources on LAVA-1207, partnered programs, and our pipeline. This is a decision to prioritize our programs with the greatest potential to benefit patients. We are grateful to the patients, their families, and the investigators who participated in the trial and contributed to this research on the Gammabody platform. We garnered a lot of knowledge from this trial and are resolute in our commitment to apply these learnings to the Gammabody platform, to contribute to the development of immuno-oncology products to treat patients with cancer in areas of unmet need."

09:07 EDT LPL Financial: Forte Financial joins broker-dealer, RIA, custodial platforms - LPL Financial LLC announced that financial advisor Brian Olson CFP, has joined LPL Financial's broker-dealer, RIA and custodial platforms. He reported having served approximately $150 million in advisory, brokerage and retirement plan assets, and joins LPL from Edward Jones. With the move to LPL, he founded Forte Financial Planning with a mission to help people navigate the complex world of finance and invest in their future. Olson's background in institutional investing, pension administration, 401(k) management and credit data allows him to offer a diverse perspective to serve clients more holistically. He is joined by longtime Client Service Manager Mariann Rubin.

09:06 EDT Shoals Technologies appoints Brandon Moss as CEO - Shoals Technologies announced the appointment of Brandon Moss as Chief Executive Officer, CEO, effective July 17th. Moss will succeed interim CEO and President Jeff Tolnar, who will continue to serve as Shoals' President. Moss has extensive experience managing and scaling businesses for long-term growth, driving new market penetration and developing strategic global partnerships. Prior to joining Shoals, he was most recently President of the Tools, Components, & Assembled Solutions Group at Southwire Company.

09:05 EDT HealthEquity appoints Lucania as CFO - HealthEquity announced that James Lucania has been announced as the Company's Executive Vice President and Chief Financial Officer, CFO, with his term to begin following the filing of the Company's Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission for the fiscal second quarter in September, succeeding Tyson Murdock, who will remain our CFO until then to assist with a smooth and orderly transition. Most recently, Lucania served on the leadership team of Ascensus Holdings, as Chief Financial Officer since 2016.

09:04 EDT AgriFORCE Growing Systems provides update on UNTHINK Awakened Flour - AgriFORCE Growing Systems provided an update on the qualification of its UN(THINK) Awakened Flour. Recent production and lab work has finalized the commercial readiness of its Awakened Flour Hard Red Wheat, a one-of-a-kind germinated wheat flour appropriate for making breads. Internal testing continues, evaluating nutritional content, taste, and texture. UN(THINK) Awakened Flour in both Soft White Wheat (for baking) and Hard Red Wheat (for bread) is now available for B2B customers in Canada and the U.S. and AgriFORCE plans to expand sales into the direct-to-consumer market after the summer.

09:02 EDT MongoDB announces new education partnerships - MongoDB announced new education partnerships and initiatives to enable and empower future developers through education and help close the widening software-development skills gap globally. To ensure the training is accessible to more developers globally, MongoDB has established distribution partnerships with Coursera and LinkedIn Learning, both with networks of millions of global learners. And, to ensure that developers from traditionally underrepresented groups have an opportunity to gain skills with MongoDB Atlas, new partnerships with Women Who Code, MyTechDev, and Lesbians Who Tech & Allies will provide free certification to 700 developers. In addition to these partnerships, the MongoDB for Academia program now offers new benefits for educators such as free MongoDB Atlas credits and certifications. MongoDB University is releasing new online learning courses to reskill database administrators and professionals that use SQL-a querying language for relational databases-on how to take advantage of non-relational database technologies.

09:01 EDT Logitech down 10% in pre-market after CEO departure, Citi downgrade - Shares of Logitech are down 10% to $6.33 per share at $57.57 in pre-market trading. The company announced the departure of its CEO Bracken Darrell yesterday evening in order to pursue another opportunity, and the stock was downgraded to Neutral at Citi this morning on this "sudden and unexpected" transition.

08:55 EDT Coherent unveils new PH20 SmartWeld+ laser technology for EVs - Coherent "introduced its new PH20 SmartWeld+ laser processing heads optimized for precision control of welding depths that are ideal for electric vehicle manufacturing applications. The exponential growth in battery manufacturing for electric vehicles is driving the demand for next-generation laser processing systems that can produce the highest-quality welds in batteries while accelerating manufacturing throughput and maintaining competitive cost of ownership. The PH20 SmartWeld+ from Coherent is now available with up to 6 kW of power, enabling precise control of penetration depth, even for long weld seams, such as those found in individual battery cells. The PH20 SmartWeld+ can be used with single-mode fiber lasers of up to 2.5 kW, and with adjustable ring mode laser sources. The PH20 SmartWeld+ can be paired with several lasers from Coherent, including the HighLight FL CSM ARM, the HighLight FL SM, and the PowerLine FL 1000/1500." Shares of Coherent are up 7.2% in pre-market trading at $45.91.

08:51 EDT Brera Holdings sings LOI to acquire majority stake in UYBA Volley - Brera Holdings signed an exclusive Letter of Intent to acquire majority ownership of the Italian Serie A1 women's professional volleyball team UYBA Volley S.s.d.a.r.l., known as E-Work Busto Arsizio based in Busto Arsizio, north of Milan. Under the LOI, Brera or its subsidiary, Brera Milano S.r.l., intends to acquire 51% of the share capital of UYBA Volley. Brera Holdings expects the acquisition of its majority stake in UYBA to close by June 28, 2023. The acquisition will be subject to the Company's entry into a definitive purchase agreement and satisfaction of all related terms and conditions.

08:47 EDT LiveOne provides update on PodcastOne's planned spin-out - LiveOne provided an update on its planned spin-out of PodcastOne as a separate public company and other updates. PodcastOne's S-1 Registration Statement Declared Effective by the SEC; Repays $3 Million of PodcastOne's convertible debt; Increases Special Dividend from 12% to ~19%; Extends Record Date to Coincide with Approval for Planned Listing on National Exchange;PodcastOne Plans to File Its 2023 FY Audited Financial Statements by June 29, 2023 as Requested by Nasdaq as Part of Its New Listing Review; LiveOne to Own ~74% of PodcastOne's Outstanding Shares Post Spin-Out; Each LiveOne Share Held as of Record Date Expected to Receive ~.048 Shares of PodcastOne in the Special Dividend. PodcastOne's planned direct listing, amount of the special dividend and LiveOne's shareholders' dividend eligibility shall be subject to obtaining approval from the applicable national exchange and compliance with applicable rules and regulations and trading and listing requirements. There can be no assurance that PodcastOne's efforts will result in the consummation of the proposed direct listing and/or special dividend.

08:43 EDT Evoke Pharma to host KOL webinar on GIMOTI - Evoke Pharma announced that it will host a key opinion leader, KOL, webinar on June 22, 2023 at 11:00am ET to discuss the healthcare resource utilization data related to GIMOTI usage presented in a plenary session at DDW 2023 annual conference. The event will feature Dr. David C. Kunkel, Gastroenterologist and Associate Professor of Medicine at UC San Diego Health and moderated by Yale Jen Ph.D., Senior Biotech Analyst at Laidlaw and Company.

08:41 EDT Greenlane announces launch of DaVinci ARTIQ Cooling Vaporizer - Greenlan announced the launch of the DaVinci ARTIQ, the newest in a line of premium portable vaporizers. "The launch of the DaVinci ARTIQ is another example of the innovative technology and products that are at the forefront of Greenlane," said Craig Snyder, CEO of Greeenlane. "Using DaVinci's clean technology, this vaporizer adds an added dimension of an even smoother, cooler vapor to our product line. We look forward to continuing to develop and offer both new and improved products that consumers desire."

08:40 EDT Expion360 introduces e360 SmartTalk Battery - Expion360 has introduced a new e360 SmartTalk Battery for powering electric golf carts and other light electric vehicles. The 48 Volt GC2 lithium iron phosphate battery was engineered to set a new standard for LEVs, combining intelligent wireless mobile management capabilities and outstanding capacity with superior construction and durability.

08:37 EDT Mirum Pharmaceuticals: Data from Livmarli evaluating ALGS patients published - Mirum Pharmaceuticals announced that data from LIVMARLI or maralixibat, oral solution clinical studies evaluating patients with Alagille syndrome, ALGS, were published in Hepatology. LIVMARLI is the first and only approved treatment for cholestatic pruritus in patients with Alagille syndrome three months of age and older. The overall findings from the retrospective analysis suggest that patients with ALGS treated with LIVMARLI who meet the identified prognostic parameters may have improved six-year survival and clinical outcomes. In the analysis, 46 pre-specified variables were evaluated as potential predictors of event-free and transplant-free survival from the LIVMARLI ALGS clinical program. Patients were assessed for up to six years; EFS was defined as absence of liver transplant , surgical biliary diversion SBD , hepatic decompensation, or death; TFS was absence of LT or death..."Complications of cholestasis, including refractory pruritus, are among the main indications for liver transplantation in patients with Alagille syndrome and many children will unfortunately require a liver transplant before adulthood," said Ronald J. Sokol, MD, chief scientific officer, child health, Children's Hospital Colorado. "This six-year analysis provides important insight into which markers predict transplant-free and event-free survival in those receiving LIVMARLI, and therefore can help guide medical management of patients receiving LIVMARLI."

08:33 EDT Biodexa Pharmaceuticals says all resolutions passed at AGM - Biodexa Pharmaceuticals announces that at its Annual General Meeting and subsequent General Meeting held earlier today, all resolutions put to the Company's shareholders were duly passed.

08:33 EDT NeuBase Therapeutics announces 1-for-20 reverse stock split - NeuBase Therapeutics will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, to be effective as of 5:00 p.m. Eastern Time today, June 14, 2023. The Company's common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Thursday, June 15, 2023. Following the reverse stock split, the Company's common stock will continue to trade on The Nasdaq Capital Market under the symbol "NBSE" with the new CUSIP number, 64132K201. The reverse stock split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on The Nasdaq Capital Market. The reverse stock split will reduce the number of issued and outstanding shares of the Company's common stock from approximately 33.8 million to approximately 1.7 million.

08:30 EDT Imax extends current share-repurchase program through June 30, 2026 - Imax announced a 3-year extension to the company's share-repurchase program through June 30, 2026. The current share-repurchase program authorized the company to repurchase up to $400M of its common shares, of which approximately $191.5M remains available, and was set to expire on June 30, 2023.

08:24 EDT Siyata Mobile launches Mobile Command Center solution - Siyata Mobile launched its latest product, the Siyata Mobile Command Center, an all-in-one, mobile communications solution with built-in redundancy primarily for providers of Emergency Management Services that need to set up a mobile telecommunications command center in the field.

08:19 EDT StorageVault Canada partners with Toronto Blue Jays - STORAGEVAULT has been named the Official Self Storage and Portable Storage Provider of the Toronto Blue Jays. The self storage brands of Access Storage, Sentinel Storage and Depotium Mini Entrepot will all benefit from this partnership. Additionally, the portable storage brands of Cubeit Portable Storage, StorageVault Containers and FlexSpace Logistics are included in the agreement. The partnership with the Toronto Blue Jays provides StorageVault's brands with national marketing rights and broadcast and in-stadium signage.

08:18 EDT Avadel Pharmaceuticals sponsors AASM Foundation's 2023 YIRF - Avadel Pharmaceuticals announced leader sponsorship of the American Academy of Sleep Medicine, AASM, Foundation's 15th Annual Young Investigators Research Forum, YIRF. This will be Avadel's third year as lead sponsor of the YIRF program, which takes place March-June 2023, with virtual events and in-person events. "At Avadel, we're passionate about supporting the sleep community, including both people with sleep disorders, as well as scientists advancing sleep research," said Jennifer Gudeman, PharmD, Senior Vice President, Medical and Clinical Affairs at Avadel. "Our ongoing partnership with the AASM Foundation stems from a communal goal to expand the field of sleep medicine for the benefit of patients. We're proud to support this vital training program with hopes that future discoveries from these early career investigators will result in new ways to better improve the lives of those with disorder sleep conditions, like narcolepsy."

08:16 EDT Cue Biopharma to present at FOCIS 2023 annual meeting - Cue Biopharma announced that it will deliver an oral presentation on its Immuno-STAT platform and biologics as well as a poster on the company's bispecific protein, CUE-401, for the treatment of autoimmune and inflammatory diseases at the Federation of Clinical Immunology Societies, FOCIS, 2023 Annual Meeting, being held June 20-23, 2023 in Boston, Massachusetts. Oral Presentation: Title: Immuno-STAT Platform: TCR-selective Engagers for Selective Targeting of IL-2 to Tumor-Specific T Cells. Dr. Quayle will describe the company's CUE-100 series of Immuno-STAT biologics, designed to enable selective targeting of the immunostimulant cytokine interleukin-2 to tumor specific T cells for enhanced efficacy and safety profiles. Proof of concept for this platform has been achieved with clinical data from CUE-101, the company's lead candidate. The data has demonstrated anti-cancer efficacy with a favorable tolerability profile and supports potential registrational paths for both CUE-101 as a monotherapy in third line recurrent/metastatic human papillomavirus 16+ head and neck squamous cell carcinoma, and CUE-101 in combination with KEYTRUDA in first line R/M HPV16+ HNSCC. Additionally, Dr. Quayle will discuss the modularity of the Immuno-STAT platform, which has enabled rapid generation of additional Immuno-STAT candidates targeting other tumor antigens, such as mutated KRAS or Wilms' Tumor 1. Poster Presentation: Title: CUE-401: A Novel IL-2/TGF-beta Fusion Protein for the Induction of CD4+ FOXP3+ Regulatory T Cells. Cue Biopharma's collaborator, Dr. DiPaolo, will discuss in vitro and in vivo data demonstrating the potential of CUE-401, the company's novel bispecific protein designed to induce and expand regulatory T cells for the treatment of T-cell mediated autoimmune and inflammatory diseases.

08:14 EDT Hoth receives approval to proceed with Phase 2a clinical trial of HT-001 - Hoth Therapeutics announced that it has received written approval from the University of Texas MD Anderson Cancer Center Institutional Review Board, or IRB, to proceed with its First-in-Human, or FIH, Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors, or EGFRi. This clinical trial is a randomized, placebo-controlled, parallel Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi.

08:13 EDT Hitek Global receives government award for Nasdaq listing - Hitek Global received a government reward of RMB 1 million for its listing to the Nasdaq Capital Market on March 31, 2023. This significant recognition highlights the Company's contribution to the local business community.

08:12 EDT CoreCivic enters into new lease agreement with state of Oklahoma for DCF - CoreCivic announced it has entered into a lease agreement with the Oklahoma Department of Corrections for the company-owned, 1,670-bed Davis Correctional Facility, DCF, which the Company currently operates under a management contract with ODOC that is currently scheduled to expire on June 30, 2023. CoreCivic expects to enter into a 90-day contract extension for the current management contract, after which time operations will transfer from CoreCivic to ODOC in accordance with the new lease agreement. The new lease agreement includes a base term commencing October 1, 2023, with a scheduled expiration date of June 30, 2029, and unlimited two-year renewal options. Terms of the 90-day contract extension are expected to remain consistent with the existing management contract at the DCF. Annual rental revenue generated from the ODOC at the DCF under the new lease agreement will be $7.5 million during the base term and will be reported in the CoreCivic Properties business segment upon lease commencement.

08:12 EDT Motus GI Holdings showcases Pure-Vu Gen 4 Gastro, Colon System at IECED - Motus GI Holdings announced that the Pure-Vu Gen 4 Gastro and Colon system was featured during the 9th Ecuadorian Institute of Digestive Diseases Live Endoscopy Course 2023 at the Pentax Learning Center, which is considered one of the most important digestive medicine annual events held in the Latin American region with over 1,000 physicians registered. During a live case conducted at the event by Dr. Carlos Robles-Medranda, Head of the Endoscopy Service at the Ecuadorian Institute of Digestive Diseases and Director of the Pentax Training Center Ecuador, the Pure-Vu system was used to support an underwater endoscopic mucosal resection. A UEMR is a polypectomy technique where the colon lumen is filled with distilled water or saline solution instead of air or carbon dioxide as used in a conventional EMR, and resection is then performed without submucosal fluid injection. The Pure-Vu Gen 4 system will have a new mode called "fluid only" that the user can select when needed to support this new use case of UEMR. The Pure-Vu Gen 4 Gastro, which is designed for use in upper gastrointestinal procedures, was also featured in a hands-on demonstration area that allowed several hundred physicians to get experience with this next generation system.

08:10 EDT IO Biotech announces achievement of Phase 3 trial recruitment milestone - IO Biotech announced that it has randomized 225 patients in its global Phase 3 clinical trial for IO102-IO103, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, in patients with advanced melanoma. This clinical milestone is significant as the Phase 3 trial protocol calls for an interim analysis of overall response rate one year after 225 patients have been enrolled. Data obtained from this interim analysis, if positive, could allow for submission of a Biologics License Application for an accelerated approval in the United States. Additionally, the company announced that it is increasing the number of patients to be enrolled in the Phase 3 trial to 380 patients, which could potentially accelerate the time to reach the primary end point of progression free survival. If the data are supportive, the PFS endpoint would serve as the basis for submitting marketing applications on a global basis. Mai-Britt Zocca, Ph.D., President and CEO of IO Biotech said, "With the momentum of enrollment building in this trial, we are taking the opportunity to increase the target for full enrollment by 80 patients, which will potentially accelerate the timeline to the primary endpoint of PFS. Even with this increase in target enrollment to 380 patients, we continue to expect to reach full enrollment in this trial by the end of this year and we continue to expect our cash to support our activities through the third quarter of 2024."

08:09 EDT PDS announces efficacy threshold achieved for VERSATILE-002 Phase 2 trial - PDS Biotechnology announced the Company achieved the threshold for efficacy as per investigator assessment in Stage 2 of the VERSATILE-002 Phase 2 clinical trial investigating PDS0101 in combination with Merck's anti-PD-1 therapy, KEYTRUDA, for the treatment of unresectable, recurrent or metastatic human papillomavirus 16-positive head and neck cancer. The achievement of full recruitment of 54 patients in the ICI naive arm was announced in May 2023. The threshold for efficacy, as defined in the clinical protocol, was achieved when 14 out of the 54 immune checkpoint inhibitor naive patients enrolled achieved a confirmed objective response. Additional patients in the trial have yet to undergo imaging evaluation. Per RECIST 1.1, the standard to classify oncologic imaging outcomes in clinical trials, patients are considered to have achieved an objective response when imaging studies document tumor shrinkage of 30% or more. In VERSATILE-002, the primary endpoint requires two consecutive scans 9 to 12 weeks apart, rather than one, to be considered a confirmed objective response. Confirmation with two consecutive scans is not required to achieve an objective response in every clinical trial per RECIST 1.1. At the recent 2023 American Society of Clinical Oncology Annual Meeting, the company presented data showing 9 confirmed responses among 34 evaluable patients. Median progression-free survival of 10.4 months was also presented at the 2023 ASCO Annual Meeting along with a 12-month overall survival rate of 87.1% for patients with a CPSgreater than or equal to1. Additional patients have been assessed since data was presented at the 2023 ASCO Annual Meeting. With these additional data, a total of 14 patients have now achieved a confirmed response to date. The achievement of this endpoint suggests an additive effect of PDS0101 over published results with ICI monotherapy and is based on statistical calculations using the appropriate power and alpha. The primary endpoint in the VERSATILE-002 study is the best overall response of confirmed complete response or confirmed partial response per RECIST 1.1. The key secondary endpoints are progression-free survival, OS at 12 and 24 months, safety, and tolerability. The study utilizes a Simon's 2-stage optimum design.

08:06 EDT Skyward Specialty Insurance announces additions of several leaders, talent - Skyward Specialty Insurance announced a significant expansion of its contract and commercial surety capabilities with the addition of several experienced and highly-respected leaders and underwriting talent. Skyward Specialty has recruited Paul Abrams as assistant vice president and Emily Ingram as senior underwriter to drive the development and growth of the Company's existing SBA capabilities. Most recently, Abrams spent five years with Crum and Forester and was previously with Tokio Marine HCC Surety Group. Previously Ingram spent four years at Crum & Forester and also worked at Tokio Marine HCC and USI Midwest. Skyward Specialty also welcomed Michal Rogson as vice president and Sabina Morgenstein as underwriting manager to expand the Company's judicial and fiduciary bond business. Rogson previously spent 16 years at Tokio Marine HCC Surety Group, where she helped establish and build a strong portfolio of judicial and fiduciary bonds. Morgenstein joins the Company with more than 16 years of surety carrier experience and a specialization in court bonds, most recently at Tokio Marine HCC Surety Group.

08:06 EDT Asset Entities reaches agreement with golfer Bryson DeChambeau - Asset Entities has reached an agreement with Bryson DeChambeau, a champion in the golfing world. Mr. DeChambeau will play a pivotal role in consulting with the Company on important initiatives including expanding awareness of the Company's Discord Design, Development, and Management services.

08:03 EDT BorgWarner expects to complete PHINIA spin-off on July 3 - BorgWarner announced that it expects to complete the spin-off of PHINIA at the end of the day on July 3 as outlined in PHINIA's final information statement filing with the Securities and Exchange Commission. PHINIA common stock will be traded on the New York Stock Exchange under the ticker symbol PHIN. The first day of trading is expected to be Wednesday, July 5. In December 2022, BorgWarner announced its intent to spin off the Fuel Systems and Aftermarket segments (later named PHINIA), consistent with its Charging Forward strategy. Both companies held Investor Day events at the New York Stock Exchange on June 6.

08:02 EDT PaxMedica submits clinical trial request in Autism Spectrum Disorder - PaxMedica announced that it has submitted a request to the South African Health Products Regulatory Authority, SAHPRA, seeking approval to conduct a double-blind, placebo-controlled study, PAX-ASD-101. This trial will seek to enroll a total of 30 subjects with confirmed ASD, ages 4 to 18, at multiple sites in South Africa. This is the first new clinical trial on the safety, tolerability, and efficacy of suramin since the Company announced the results of its prior Phase II trial in 2021. Enrollment is expected to begin in Q4 2023, following SAHPRA's potential approval later this summer. PaxMedica is also preparing additional submissions for planned PAX-101 trials with other regulatory authorities outside of South Africa in 2023. PaxMedica is in the final stages of scaled manufacturing of the PAX-101 API and drug product to ensure the availability of the drug for clinical trials, registration and validation for both HAT and ASD programs.

08:01 EDT Integral Ad Science expands partnership with TikTok - Integral Ad Science announced a significant expansion with TikTok, bringing its Total Media Quality brand safety and suitability measurement product to advertisers in 23 new markets. This expansion further cements IAS's deep partnership with TikTok and adds to the seven countries where brand safety and suitability measurement went live in October 2022.

07:49 EDT Ivanhoe Electric provides update on drilling at Santa Cruz Copper Project - Ivanhoe Electric Executive Chairman Robert Friedland and President and CEO Taylor Melvin are pleased to provide an update on the drilling operations underway at the Santa Cruz Copper Project, located west of Casa Grande, Arizona. Ivanhoe Electric controls private surface land, the patented mineral rights and the associated water rights encompassing the entire Santa Cruz Project. Mr. Friedland commented: "Our hardworking team of women and men have been making steady progress at the Santa Cruz Copper Project, uncovering high-grade copper mineralization in areas that were previously unknown and expanding our technical knowledge in underground areas near conceptual development. We remain on track to deliver an important Initial Assessment of the Project by the end of Q3 2023. This first detailed study will provide us with valuable insights into the economic potential at Santa Cruz, moving us closer to building a modern, underground copper mine in Arizona. By doing so, we are aiming not only to support United States supply chain independence for electric metals but also create quality jobs for Arizonans." The infill and development drilling program continues to characterize key geotechnical, hydrogeological and metallurgical characteristics of the Santa Cruz Deposit. Multi-purpose infill and development drill holes, not previously included in the December 31, 2022, Mineral Resource Estimate, have intersected high-grade copper oxide and chalcocite mineralization, some in areas where copper mineralization was previously undefined. Drill hole SCC-125 targeted definition and expansion of the high-grade Exotic Copper Domain in the current Mineral Resource Estimate and intersected visible atacamite, chrysocolla, and chalcocite mineralization starting at a downhole depth of approximately 586 meters. Drill hole SCC-136, located in the northwestern region of the Santa Cruz Deposit, targeted a mineralized and resource controlling fault, but also intersected visible copper oxide and chalcocite mineralization starting at a downhole depth of approximately 432 meters in an area undefined by previous drilling. These recent intersections continue to demonstrate and provide valuable insights into the extent and consistency of the mineral resource and areas for potential additions. The assay results for drill holes SCC-125 and SCC-136 are pending.

07:42 EDT NLS Pharmaceutics announces safety data from in vitro drug interaction studies - NLS Pharmaceutics announced data from five recently completed in vitro drug-drug interaction studies investigating the potential for DDI of mazindol, a triple monoamine reuptake inhibitor and partial orexin-2 agonist, as well as its hydrolyzed metabolite. Typical DDI studies include Cytochrome P450, UDP glucuronosyltransferase and transporter inhibition and induction studies to evaluate whether mazindol affects the pharmacokinetic effect of other drugs. In addition, in vitro studies are conducted with CYP and transporter substrates to evaluate whether other drugs can affect mazindol PK. Following U.S. Food and Drug Administration guidelines, the in vitro DDI studies were designed to evaluate the drug interaction potential across a wide range of metabolic enzymes and transporters when co-administered with mazindol. The mazindol in vitro studies examined the following: CYP Inhibition in Human Liver Microsomes; CYP Induction in Cultured Human Hepatocytes; CYP and UGT Reaction Phenotyping; UGT Inhibition in Human Liver Microsomes; ATP-binding case and solute carrier Transporter Inhibition and Substrate Potential in Cells and Vesicles. Results of the in vitro perpetrator studies showed that mazindol and its hydrolysis metabolite do not have the potential to inhibit or induce the metabolism/transport of concomitant medications. Based on these in vitro data, it can be concluded that mazindol and the hydrolysis metabolite are not inhibitors of CYPs, UGTs, or transporters. Therefore, mazindol does not affect the PK of concomitant medications. Results of the in vitro victim studies showed that mazindol is not metabolized by CYPs or UGTs and is not transported by BCRP, OAT1, OAT3 and OCT2. Only the hydrolysis metabolite is a P-glycoprotein substrate; thus a clinical DDI study of mazindol is planned to quantify the potential for an increase in the hydrolyzed metabolite exposure in the presence of a Pgp inhibitor. Otherwise, concomitant medications are not expected to affect the PK of mazindol. Beginning in July 2023, NLS will initiate the AMAZE development program for Mazindol ER, consisting of two pivotal Phase 3, randomized, double-blind, placebo-controlled, multicenter studies in the U.S. designed to assess the safety and efficacy of mazindol in patients with narcolepsy type 1 compared to placebo. These two studies will enroll a total of 100 NT1 patients. Mazindol ER will be administered at fixed doses of 3 mg once daily for a total of eight weeks. A 52-week open-label extension will further evaluate the long-term safety and tolerability of Mazindol ER in NT1 patients. Topline data from the double-blind studies are expected in late 2024.

07:37 EDT Blue Water Biotech to acquire six FDA-approved drugs for $8.5M - Blue Water Biotech announced the signing of an Asset Purchase Agreement with WraSer and Xspire Pharma for the purchase of six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain management. Under the terms of the Agreement, Blue Water Biotech will purchase the WraSer Assets for a total of $8.5 million cash consideration payable in three tranches: at signing, upon closing and within one year of closing. In addition, WraSer shall receive 1.0 million restricted shares of Blue Water's common stock on the closing date. The closing of the transaction is subject to certain customary closing conditions, as well as WraSer's delivery of 2022 audited financial statements for WraSer's parent company, Legacy-Xspire Holdings, LLC, to Blue Water. Blue Water will assume management of the WraSer Assets during the audit period. The audited financial statements will be publicly filed promptly after completion of the audit. The assets under the Agreement include the patents related to ZONTIVITY, a medication for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease, as well as additional products for the treatment of hypertension, otitis media, and pain management. ZONTIVITY, a once daily pill approved in 2014, is a first-in-class protease activated receptor-1 inhibitor which mediates the cellular effects of thrombin to reduce the risk of major adverse cardiovascular events and major adverse limb events when used in addition to aspirin and/or clopidogrel in patients with PAD. In a pivotal Phase 3 clinical trial, ZONTIVITY was shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization, with 13,186 patients evaluated for safety and 2,187 patients treated with ZONTIVITY for more than three years. This Agreement also includes the purchase of licenses to market and distribute two antibiotic otic products, OTOVEL and CETRAXAL, and their authorized generics currently marketed and distributed by WraSer. OTOVEL, ciprofloxacin and fluocinolone acetonide, is used to treat acute otitis media in children 6 months of age and older who have a tiny cylinder tube, known as a tympanostomy tube, inserted in their eardrum that prevents excess fluid in the middle ear. While tympanostomy tubes are typically placed as a result of multiple ear infections within a short timeframe, they do not prevent AOM, and one study found that over 80% of children had an episode of AOM within 18 months of tympanostomy tube placement. OTOVEL, which contains an antibiotic to treat the infection and an anti-inflammatory to reduce pain and swelling, is the first and only antibiotic and steroid ear drop available in single use vials. In two clinical studies of pediatric patients with AOM with tympanostomy tubes, children who took OTOVEL were clear of otorrhea in a median of 3.75 and 4.94 days, whereas those on antibiotic alone were not clear until a median of 7.69 and 6.83 days. The clinical studies also showed that the combination of medicines in OTOVEL had similar side effects as the separate medicines. Blue Water is currently developing a vaccine to prevent acute otitis media regardless of tympanostomy tube insertion, and the Company intends to leverage this experience and expertise in the future commercialization and marketing for OTOVEL. The second otic product included in the Agreement, CETRAXAL, ciprofloxacin otic solution available in individual unit dosing vials, is used to treat otitis externa, more commonly called swimmer's ear, in children with an intact tympanic membrane. Swimmer's ear is characterized by redness or swelling, irritation, or infection of the outer ear canal and can be very painful if left untreated, primarily impacting children that spend a lot of time in the water. In addition to ZONTIVITY and otic products, Blue Water will purchase the licensed rights to market and distribute CONJUPRI, a calcium channel blocker that can be used alone or in combination with other antihypertensive agents for the treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and MIs. Additionally, Blue Water will purchase two pain medications, TREZIX, for the treatment of moderate to moderately severe pain for which non-opioids are inadequate, and NALFON, for relief of mild to moderate pain in adults, as well as relief of the signs and symptoms related to rheumatoid arthritis and osteoarthritis.

07:35 EDT Camping World to acquire Van Boxtel RV, terms undisclosed - Camping World announced that it is set to acquire Van Boxtel RV in Green Bay, Wisconsin. The acquisition is anticipated to close in the third quarter of and will increase the company's Wisconsin location count to seven.

07:28 EDT Aldebaran Resources closes top-up financing by South32 - Aldebaran Resources completed its previously announced top-up financing with a subsidiary of South32. South32 elected to exercise its anti-dilution rights to maintain a 9.9% equity interest in the Company following the exercise of warrants announced on May 5, 2023. South32 acquired 970,000 common shares at a price of $0.73 per Common Share for total proceeds of $708,100. In accordance with the terms of the Investor Rights Agreement between the Company and South32, the issue price was set at the volume weighted average price of the Common Shares in the five day period preceding the election notice by South32. The Common Shares issued pursuant to this financing will be subject to a four month hold period in accordance with applicable securities laws. Aldebaran intends to use the funds to advance the Altar copper-gold project located in San Juan, Argentina, and for general corporate purposes.

07:24 EDT Wesdome Gold Mines announces results from drilling program at Eagle River Mine - Wesdome Gold Mines announces results from the ongoing underground exploration drilling program at the Company's wholly-owned Eagle River Mine in Wawa, Ontario. Warwick Morley-Jepson, Board Chair and Interim CEO commented, "These results continue to confirm the geometry and high grades of the 300 East Zone. The objective of drilling this zone is to define a second, higher-grade lens similar to the previously mined 303 Lens that could potentially positively impact gold production. The 303 Lens was mined primarily in 2019 and average muck grade was 46.1 g/t. Additionally, the drilling of the 300 East Zone confirms the continuity of the mineralization at depth, thus suggesting that many other similar zones, such as 808, 811, 818, 711 and 7 East, have this same potential to continue at depth... Meanwhile, we remain focused in 2023 on converting a large, inferred base into indicated and measured resources and subsequently reserves

07:19 EDT Solaris Resources reports new porphyry discovery at Patrimonio - Solaris Resources announces the discovery of a significant new porphyry deposit in the first reconnaissance drill hole at the Patrimonio target, southwest of Warintza Central. Patrimonio represents the sixth porphyry deposit discovered on the Warintza Project in southeastern Ecuador. Jorge Fierro, Vice President, Exploration, commented: "Patrimonio is an exciting, new discovery, unique in terms of the intensity of mineralization and alteration within the Warintza porphyry cluster. Together with the recent discovery of a second and higher-grade porphyry center to the south of Warintza East we now distinguish as Warintza Southeast, the Patrimonio discovery provides strong validation of our exploration approach of systematic soil sampling led by senior geologist, Keller Guerra, that has also identified areas of significantly stronger soil anomalism in the Warintza West and Warintza South areas for future exploration."

07:18 EDT Green Thumb Industries to open RISE Dispensary Las Vegas on Nellis - RISE Dispensaries announced that RISE Dispensary Las Vegas on Nellis, the Company's 81st retail location in the nation, will open on June 16th. The new dispensary will hold a grand opening event on July 22nd, where profits from the day will be donated to Opportunity Village. The grand opening will be a part of the Green is Our Genre, RISE Grand Opening Tour, which will stop at every RISE Dispensary in Nevada and include music, exclusive promotions, and local food trucks.

07:16 EDT Mayfair Gold announces updated interim mineral resource estimate at Fenn-Gib - Mayfair Gold announced an updated interim mineral resource estimate at the Company's 100% controlled Fenn-Gib Gold Project, located in the Timmins region of Northeast Ontario. Based on assay results from approximately 81% of the Company's ongoing 140,000-meter infill and expansion drill program, the Fenn-Gib Zone deposit now hosts a NI 43-101 open-pit constrained Indicated mineral resource estimate of 3.38 million ounces gold at a grade of 0.93 grams per tonne Au and an Inferred mineral resource of 0.16Moz Au at 0.85 gpt Au. The near-surface Fenn-Gib gold mineralization is broadly disseminated striking east-west on the Pipestone Fault over more than 1.5 kilometers and is over 500m wide at the west end. Mayfair Gold President and CEO Patrick Evans commented: "We are pleased to report both a 16% increase in Indicated resource ounces and an 8% increase in Indicated resource grade. The increase in the Indicated resource ounces reported today comes from a combination of the Expansion Zone in the center of the Fenn-Gib deposit, the footwall mafics in the northern portion of the conceptual pit, the east side of the higher-grade Main Zone, and from the conversion of Inferred to Indicated resource ounces. The Fenn-Gib mineralization remains open for further expansion in most directions, and we are excited about the potential to further increase the resources with the ongoing drill program supported by three drill rigs. Mayfair expects to provide a further updated mineral resource estimate on the Fenn-Gib open-pit deposit in early 2024. Resource drilling on the higher-grade Footwall Zone, located approximately 100m to the northwest of the Fenn-Gib Zone, is ongoing and supported by two drill rigs. Based on results to date, Mayfair expects to report a maiden underground Footwall Zone resource in early 2024." Highlights of the Updated Fenn-Gib Mineral Resource Estimate at 0.40 gpt Au cut-off grade: Fenn-Gib Zone open-pit constrained Indicated resource of 3,382,788 oz at 0.93 gpt Au; Fenn-Gib Zone open-pit constrained Inferred resource of 157,292 oz at 0.85 gpt Au.

07:14 EDT Mercury Systems hosts U.S. Senator Shaheen at Hudson facility - Mercury Systems on Friday hosted U.S. Sen. Jeanne Shaheen at its Hudson, NH, facility, showcasing the company's technologies and manufacturing capabilities that support critical defense programs across the U.S. and international defense communities. "We were honored to welcome Senator Jeanne Shaheen to our Hudson facility to share the work our dedicated and skilled workforce is doing to accelerate innovation and deliver mission-critical capabilities to our military customers," said Brian Perry, Mercury's Senior Vice President for Mission Systems. "As an industry leader at the intersection of high tech and defense, we deeply appreciate Senator Shaheen's support for national security and her role in keeping New Hampshire at the forefront of advanced technology and economic growth."

07:12 EDT Ventyx Biosciences initiates dosing in Phase 1 trial of VTX3232 - Ventyx Biosciences announced that the first subject has been dosed in a Phase 1 trial of VTX3232, a novel central nervous system-penetrant NLRP3 inhibitor. The Phase 1 trial of VTX3232 is a two-part, randomized, double-blind, placebo-controlled single ascending dose and multiple ascending dose trial designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VTX3232 in adult healthy volunteers. The trial will explore a broad range of doses and will include serial cerebrospinal fluid sampling to assess brain exposure. Topline results from the trial are expected in the first half of 2024. There is a growing body of preclinical data suggesting NLRP3's role as a central driver of neuroinflammation and thus we believe VTX3232 may have therapeutic potential in a range of neuroinflammatory conditions with high unmet medical need, including Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis, among others. In addition to VTX3232, we are also evaluating VTX2735, a peripherally restricted NLRP3 inhibitor, in a Phase 2 proof-of-mechanism trial in patients with familial cold autoinflammatory syndrome. FCAS is the most common subset of cryopyrin-associated periodic syndrome, a group of rare autoinflammatory conditions caused by gain-of-function mutations in the NLRP3 gene. Beyond CAPS, we believe VTX2735 may have therapeutic potential across a broad range of chronic inflammatory conditions that are characterized by NLRP3-induced excess IL-1beta, including large dermatologic, rheumatic and cardiovascular disease.

07:11 EDT Patriot Battery Metals announces core assays for 2023 winter drill program - Patriot Battery Metals announced core assays for the next series of drill holes completed as part of the 2023 winter drill program, which recently concluded at its wholly owned Corvette Property, located in the Eeyou Istchee James Bay region of Quebec. The winter phase of the 2023 drill campaign was focused on the CV5 Pegmatite, located approximately 13.5 km south of the regional and all-weather Trans-Taiga Road and powerline infrastructure. Core assays, for the drill holes reported herein, cover the CV5 Pegmatite's recently defined eastward extension, the high-grade Nova Zone and the recently defined westward extension. Drill hole CV23-148 targeted the Nova Zone and returned a wide and high-grade intercept of 95.3 m at 1.62% Li2O, including 47.6 m at 2.09% Li2O or 4.1 m at 4.44% Li2O. The high-grade result affirms the interpretation that the Nova Zone extends continuously over a strike length of at least 1.1 km - from drill holes CV23-132 to 108. Strong grades and widths were returned in drilling over the recently defined westward extension, highlighted by drill hole CV23-160A, which returned 127.7 m at 1.78% Li2O, including 50.1 m at 2.43% Li2O. Other drill holes in this area, with assays reported herein, include CV23-172, CV23-182, and CV23-187. Additionally, drill hole CV23-174, located proximal to the westward extension, returned a strong intercept of 44.2 m at 0.99% Li2O, including 15.3 m at 2.58% Li2O. Drill core sample assays for two holes remain to be reported over the westward extension area of the CV5 Pegmatite. This includes a continuous 93 m interval of dominantly spodumene-bearing pegmatite in the most westerly drill hole completed through the end of the winter program, and a continuous 139 m interval of dominantly spodumene-bearing pegmatite in the final drill hole of the 2023 winter program. Assay results for holes reported herein over the far eastern portion of CV5, as is currently defined, returned variable grades and widths of lithium mineralized pegmatite. Results include 51.2 m at 0.59% Li2O, including 10.1 m at 0.87% Li2O and 9.3 m at 0.91% Li2O, and 27.5 m at 0.40% Li2O, including 3.2 m at 2.22% Li2O. Internal fractionation commonly leads to lower-grade pegmatite being immediately adjacent to higher-grade pegmatite. Considering the wide and continuous widths of pegmatite in these holes, at 49.9 m and 27.5 m, respectively, the grades returned are very encouraging with respect to the potential for additional and proximal higher-grade zones to be present. The pegmatite in this area remains open up-dip, down-dip, and along strike eastwardly. Through the 2023 winter drill program, the CV5 Pegmatite has been traced continuously by drilling as a principally continuous spodumene-mineralized body over a lateral distance of at least 3.7 km and remains open along strike at both ends and to depth along most of its length.

07:05 EDT Plug Power to supply Blue EnerFreeze with green hydrogen, fuel cell solutions - Plug Power will supply Blue EnerFreeze, the energy subsidiary of STEF, with a complete green hydrogen ecosystem across two distribution centers, before potentially expanding further into their network of over 100 sites. One of the distribution centers is close to Paris, France and the other is close to Madrid, Spain. Temperatures in STEF's chilled and frozen food storage warehouses can plunge to negative 30 degrees Celsius, in worst cases. Under these conditions, lead acid battery-powered forklifts lose their charge quickly. Meanwhile, hydrogen fuel cells display superior performance in cold storage environments, offering higher asset utilization and increased levels of autonomy in demanding, typically multi-shift, mobility applications. The transition from lead-acid batteries to Plug's hydrogen fuel cells will potentially improve STEF's forklift labor productivity due to maximum power over an entire shift. Battery-powered lift trucks lose approximately 14% of their speed over the last half of the battery charge. Unique to cold storage applications the switch to fuel cells allows operators to stay productive longer. This also means that lift truck operators can continue working in the cold storage facility for a full shift strengthening their comfort and avoiding changing of the batteries.

07:04 EDT Tilray expands beer portfolio, launches Good Supply Beer - Tilray Brands announced the launch of Good Supply Beer, a new light beer brand and premium lager. Good Supply beer is now available year-round in 16-ounce cans across Georgia, Connecticut, and New York with added distribution rolling out this summer. Ty Gilmore, President, U.S. Beer, Tilray Brands, said, "...Good Supply is uniquely positioned to offer a competitively priced and delicious light beer crafted with premium ingredients and brewing techniques."

07:03 EDT ArcelorMittal, John Cockerill to develop low temp iron electrolysis plant - ArcelorMittal and John Cockerill announce plans to construct the world's first industrial-scale low temperature, temp, iron electrolysis plant. The Volteron plant, which in a first phase will produce between 40,000 and 80,000 tonnes a year of iron plates, is targeted to start production in 2027. Once the technology has been proven at this scale, the intention is to increase the plant's annual capacity to between 300,000 and 1 million tonnes. ArcelorMittal and John Cockerill have been working together on an innovative electrochemical process to transform iron oxide into iron plates for the last few years. Commenting, Brad Davey, EVP and head of corporate business optimisation, ArcelorMittal, said: "It is a significant moment for ArcelorMittal, and for the global steel industry. Direct electrolysis is a disruptive, breakthrough technology. Although the technology needs to mature, it could revolutionise how steel is made, removing carbon entirely from steelmaking. We intend to be pioneers in that process."

07:02 EDT 2seventy Bio announces pause in SC-DARIC33 trial due to fatal SAE - 2seventy Bio announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute Myeloid Leukemia, or AML, has been paused by Seattle Children's, the company's partner and the regulatory sponsor of the study. The pause was instituted as part of the clinical study protocol stopping rules in response to a recent fatal serious adverse event, or SAE, and was followed by the required notification to the FDA. The root cause of this SAE and its potential relationship to the study drug is currently under investigation. PLAT-08 is the Phase 1 study of SC-DARIC33 in relapsed/refractory pediatric AML, conducted by Seattle Children's, and couples 2seventy bio's DARIC T cell platform with Seattle Children's expertise in oncology cell therapies. This study is a first-in-human investigation of the DARIC T cell platform. The SAE occurred in the first patient treated at the second dose level in the Phase 1 trial.

06:53 EDT Eagle granted QIDP designation for CAL02 by FDA - Eagle Pharmaceuticals announced that the FDA has granted Qualified Infectious Disease Product, or QIDP, Designation under the Generating Antibiotic Incentives Now, or GAIN, Act and Fast Track Designation for CAL02, a first-in-class non-biological bacterial virulence neutralizer, anti-infective agent being developed to treat severe community-acquired bacterial pneumonia, or SCABP, as an add-on therapy to standard of care. "Receiving QIDP designation underscores the importance of CAL02 for potentially treating SCABP, and the Fast Track Designation allows us to work even closer with the FDA to bring patients a new treatment option sooner as we would also be eligible to request Priority Review for our application. Antibiotics alone, unfortunately, cannot win the war against pneumonia. CAL02 would serve as an add-on to standard of care antibiotic therapy for the prompt treatment of severe bacterial pneumonia and its devastating consequences," stated Scott Tarriff, President and CEO. Eagle believes that CAL02 could also be eligible for breakthrough therapy designation. Eagle is also further developing the patent estate to protect the intellectual property resulting from the development of this novel, first-in-class therapy. CAL02 is currently protected by issued U.S. Patent No.10,744,089, which extends until September 2035, and may be eligible for Patent Term Extension for up to five years until 2040. SCABP is a worldwide prevalent infectious disease associated with high morbidity and mortality, despite the availability of vaccines, effective antibiotic regimens, and state-of-the-art critical care therapy.

06:46 EDT TransUnion announces strategic partnership with Truework - TransUnion announced a strategic partnership with Truework, a leading provider of verification of income and employment services in the U.S. Truework provides a comprehensive and efficient one-stop platform for VOIE information while also giving consumers greater control of their personal and financial information. This strategic partnership follows a strategic minority investment TransUnion made in Truework earlier this year. Together, Truework and TransUnion intend to provide comprehensive income verification coverage with robust credit data. This will give verifiers an up-to-date view of consumers, enabling better insights and more efficient decision making.

06:33 EDT Hut 8 Mining signs agreement with Interior Health - Hut 8 Mining has signed an agreement with Interior Health, trusted health authority that delivers public health, hospital care, long-term care, community-based and primary health care services to people across southern British Columbia, to support their operations by delivering safe, secure, and reliable colocation services from the company's flagship Kelowna data center through 2028.

06:27 EDT Shell updates strategy to deliver shareholder returns, create less emissions - Shell will update investors on its strategy to create more value with less emissions, and deliver increased shareholder returns through a balanced energy transition. "We are investing to provide the secure energy customers need today and for a long time to come, while transforming Shell to win in a low-carbon future," said Shell Chief Executive Officer, Wael Sawan. An enhanced focus on performance and stronger capital and cost discipline will underpin higher shareholder distributions of 30-40% of CFFO through the cycle, compared with 20-30% previously, through a combination of dividends and share buybacks. Shell will raise the dividend per share by an expected 15%, effective from the second quarter 2023 interim dividend, payable in September, and commence share buybacks of at least $5 billion for the second half of 2023, subject to Board approval. Shell also confirms it will: Grow its leading Integrated Gas business and maintain leadership in the global liquefied natural gas market; Extend its advantaged position in Upstream to achieve cash flow longevity by stabilising liquids production to 2030; Leverage its brand, customer relationships, and trading strengths. Shell will: Strengthen the performance of its Marketing business, while building leading positions in low-carbon fuels and electric vehicle charging; Invest in hydrogen and carbon capture and storage; Repurpose its Energy and Chemicals Parks footprint to offer more low-carbon solutions to its customers while undertaking a strategic review of its Energy and Chemicals Park assets on Bukom and Jurong Island in Singapore, and further high-grading its European footprint; Selectively invest in Power. Shell is making good progress towards its target to become a net-zero emissions energy business by 2050. Shell will continue to make progress by: Aiming to achieve near-zero methane emissions by 2030 and to eliminate routine flaring from its Upstream operations by 2025, moving faster than the World Bank's Zero Routine Flaring 2030 initiative; Planning to invest $10-15 billion across 2023 to 2025 to support the development of low-carbon energy solutions including biofuels, hydrogen, electric vehicle charging and CCS. "We need to continue to create profitable business models that can be scaled at pace to truly impact the decarbonization of the global energy system. We will invest in the models that work - those with the highest returns that play to our strengths," said Sawan.

06:09 EDT Maxeon Solar announces collaboration with Samsung - Maxeon Solar (MAXN) announced a collaboration with Samsung (SSNLF) to integrate Maxeon's SunPower One residential energy solution within SmartThings' connected home platform. This integration is intended to enable homeowners to increase their energy independence, save money, and contribute to a cleaner environment.

06:04 EDT ATI Physical Therapy announces one-for-fifty reverse stock split - ATI Physical Therapy announced that its board of directors has approved a one-for-fifty reverse stock split of ATI's Class A common stock, par value $0.0001 per share. The reverse stock split was approved by ATI's stockholders at a meeting of stockholders held virtually on June 13. The reverse stock split will become effective at 4:01 p.m. Eastern Time on June 14 and the Class A Common Stock will open for trading on The New York Stock Exchange on a reverse split-adjusted basis on June 15 under the existing trading symbol. The reverse stock split is intended to increase the market price per share of the company's Class A Common Stock to regain compliance with the minimum bid continued listing requirement of the NYSE.

06:01 EDT GigaCloud approves $25M share repurchase program - GigaCloud Technology announced that its board of directors has approved a share repurchase program to repurchase up to $25.0M of its Class A ordinary shares, par value 5c, over the next 12 months. Under the share repurchase program, the Company may purchase its ordinary shares through various means, including open market transactions, privately negotiated transactions, block trades, any combination thereof or other legally permissible means. The Company plans to fund repurchases from its existing cash balance.

05:12 EDT NextDecade enters pact with TotalEnergies, GIP to support Rio Grande LNG project - NextDecade (NEXT) announced that it has entered into framework agreements with Global Infrastructure Partners, or GIP, and TotalEnergies (TTE) to enable the final investment decision, or FID, for the Rio Grande LNG project Trains 1, 2 and 3 and to provide momentum for the further development of RGLNG Train 4 and Train 5. NextDecade, GIP and TotalEnergies have entered into framework agreements whereby GIP would become a majority investor in Phase 1, and TotalEnergies would become a 16.67% investor, both subject to execution of definitive documentation and FID. The agreements are expected to further provide GIP and TotalEnergies options to invest in RGLNG Train 4 and Train 5 and options to invest in the planned carbon capture and sequestration, or CCS, project at RGLNG. In addition, TotalEnergies has agreed to purchase 5.4M tons per annum of LNG from Phase 1 for 20 years on a free on board basis indexed to Henry Hub and has options to purchase LNG from Train 4 and Train 5. TotalEnergies has also agreed to acquire in three tranches a 17.5% common stock position in NextDecade for an aggregate purchase price of $219.4M. The first tranche of $40M of NextDecade common stock was issued and sold today at $4.9837 per share. The second tranche of $110M will be issued and sold at the same price after FID on Phase 1. The third tranche will be issued and sold in an amount such that the combined stock purchases equal 17.5% of the outstanding common stock of NextDecade after the closing of the third tranche. The issuance and sale of the common stock in the third tranche will be conditioned on the approval of NextDecade shareholders. Based on current estimates, NextDecade expects to sell approximately 45.1M shares of common stock in the aggregate to TotalEnergies at an average price per share of approximately $4.86.